3 reports

  • Market drivers
  • Neutropenia market in EMEA

About Neutropenia Treatment Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms....

  • G-CSF
  • World
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • 4.3 GRANULOCYTE - COLONY STIMULATING FACTOR (G-CSF) BIOSIMILARS MARKET

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of ## biosimilars approved for use in Europe.

  • G-CSF
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited
  • Filgrastim: Biosimilar Products in Other Less Regulated Markets
  • Filgrastim: Biosimilar Products in China & Taiwan - 2/2

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and...

  • Biosimilar
  • Filgrastim
  • G-CSF
  • United States
  • Amgen Inc.